Effects of daily intake of zidovudine-stavudine on rat pregnancy outcome: biological essay
Nenhuma Miniatura disponível
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2012
Título da Revista
ISSN da Revista
Título do Volume
Editora
I R O G CANADA, INC
Autores
ANTONIO, E. Restum
FONTES, T. M. Pereira
CARVALHO, A. Moreira de
ESPIRIDIAO, S.
NAKAMURA, M. Uchiyama
KULAY JR., L.
Citação
CLINICAL AND EXPERIMENTAL OBSTETRICS & GYNECOLOGY, v.39, n.2, p.205-208, 2012
Resumo
Purpose: To evaluate the effects at term of a highly active antiretroviral drug association when administered for the whole period of rat pregnancy. Methods: Forty pregnant rats weighing about 200 g were randomly divided into four groups: a control group (Ctr = drug vehicle control, n = 10) and three experimental groups. which were treated with an oral solution of zidovudine-stavudine (Exp1x = 10/1 mg/kg b.w., n = 10; Exp3x = 30/3 mg/kg b.w., n = 10; Exp9x = 90/9 mg/kg b.w., n = 10) from ""day 0"" up to the 20th day of pregnancy. Maternal body weights were recorded at the start of the experiment and on the 7th, 14th and 20th day thereafter. At term (20th day) the rats were anesthetized and submitted to hysterotomy. Implantations, reabsorptions, living fetuses, placentae and intrauterine deaths were looked for and recorded. The collected fetuses and placentae were weighed and the concepts were examined by a stereoscopic microscope looking for external malformations. Results: No significant alterations due to the antiretroviral drug treatment could be detected regarding the number of implantations, fetuses, placentae, absorptions and malformations nor regarding maternal and fetal mortality. Conclusions: Administration of the association zidovudine/stavudine for the whole period of rat pregnancy did not interfere with the maternal, fetal and placental weight gain as well as abnormalities detectable by the employed methodology.
Palavras-chave
Rat, Pregnancy, Zidovudine, Stavudine, Adverse effects
Referências
- Anema A, 2011, AIDS RES THER, V8, DOI 10.1186/1742-6405-8-13
- BALZARINI J, 1989, J BIOL CHEM, V264, P6127
- Barreto RLB, 2004, J OBSTET GYNAECOL RE, V30, P242, DOI 10.1111/j.1447-0756.2004.00180.x
- Chirenje ZM, 2010, EXPERT REV ANTI-INFE, V8, P1177, DOI [10.1586/eri.10.79, 10.1586/ERI.10.79]
- CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801
- COOPER AJ, 1991, BRIT J SURG, V78, P1409, DOI 10.1002/bjs.1800781202
- De Clercq E, 2010, CURR OPIN PHARMACOL, V10, P507, DOI 10.1016/j.coph.2010.04.011
- Figueiro-Filho E.A., 2002, REV BRAS GINECOL OBS, V24, P647
- Grasela DM, 2000, ANTIMICROB AGENTS CH, V44, P2149, DOI 10.1128/AAC.44.8.2149-2153.2000
- GREENE JA, 1990, FUND APPL TOXICOL, V15, P201, DOI 10.1016/0272-0590(90)90176-K
- HITCHCOCK M J M, 1991, Antiviral Chemistry and Chemotherapy, V2, P125
- KAUL S, 1995, BIOPHARM DRUG DISPOS, V16, P125, DOI 10.1002/bdd.2510160207
- Khandazhinskaya A, 2010, EXPERT OPIN DRUG MET, V6, P701, DOI 10.1517/17425251003713501
- Lambert J.S., 2000, MANUAL ACOMPANHAMENT
- Litle B.B., 1989, AM J OBSTET GYNECOL, V161, P732
- Mamede J. A. V., 2000, Clinical and Experimental Obstetrics and Gynecology, V27, P227
- MAMEDE JAV, 1995, GEN PHARMACOL, V26, P523, DOI 10.1016/0306-3623(94)00237-H
- Mirochnick M, 2010, CLIN PERINATOL, V37, P907, DOI 10.1016/j.clp.2010.08.006
- Negin J, 2010, B WORLD HEALTH ORGAN, V88, P847, DOI 10.2471/BLT.10.076349
- Olfert E.D., 1993, CANADIAN COUNCIL ANI, V1
- Pavek P, 2003, J PHARMACOL EXP THER, V305, P1239, DOI 10.1124/jpet.102.048470
- Pizzo P.A., 1990, INFECT DIS, V12, P5561
- SORENSEN AM, 1993, SCAND J INFECT DIS, V25, P365, DOI 10.3109/00365549309008512
- Tam LWY, 2007, HIV MED, V8, P267, DOI 10.1111/j.1468-1293.2007.00463.x
- Wagner Adriana, 2010, Rev Bras Ginecol Obstet, V32, P556, DOI 10.1590/S0100-72032010001100007
- Watts DH, 2006, DRUG SAFETY, V29, P467, DOI 10.2165/00002018-200629060-00002